Hyperbaric oxygen therapy reduces bladder wall inflammation and promotes mucosal healing in interstitial cystitis
Hyperbaric oxygen therapy reduces bladder wall inflammation and promotes mucosal healing in interstitial cystitis
Understanding interstitial cystitis and how HBOT addresses bladder wall inflammation and mucosal barrier dysfunction
Interstitial cystitis (IC), also called bladder pain syndrome (BPS), is a chronic condition characterized by persistent bladder pain, pressure or discomfort, often accompanied by urinary urgency and frequency. It affects an estimated 3 to 8 million Americans — predominantly women — and is one of the most frustrating conditions in urology because its cause is incompletely understood and no single treatment reliably resolves it.
The pathophysiology of IC involves multiple interacting mechanisms. Damage to or dysfunction of the glycosaminoglycan (GAG) layer — the protective mucous coating of the bladder urothelium — allows urinary constituents (potassium, urea, proteins) to penetrate into the bladder wall, triggering inflammation, mast cell activation and sensory nerve stimulation. This sets up a self-perpetuating cycle of bladder wall inflammation, neurogenic sensitization and pain that standard treatments often fail to fully interrupt.
Approximately 10% of IC patients have Hunner lesions — discrete inflammatory ulcerations of the bladder wall that represent a more severe and distinct subtype of the condition. These lesions are particularly difficult to treat, tend to recur after ablation, and are associated with more severe symptoms and reduced quality of life.
HBOT addresses IC through several complementary mechanisms: suppression of the bladder wall inflammation and mast cell activation that drive symptoms, promotion of urothelial repair through growth factor and stem cell activation, improvement of pelvic tissue oxygenation, and modulation of the pelvic neuroinflammatory sensitization that amplifies IC pain. Published randomized controlled trial data confirm that HBOT produces meaningful improvements in validated IC symptom measures in patients with refractory disease.
Persistent pelvic pain, pressure or discomfort that worsens as the bladder fills
Urinary urgency — strong, sudden need to urinate, often impossible to delay
Urinary frequency — urinating 8 or more times per day, often waking at night
Pain or discomfort during sexual intercourse
Symptoms that flare with certain foods, beverages, stress or menstruation
Severely reduced quality of life from pain, urgency and sleep disruption
How HBOT addresses the bladder wall pathology of interstitial cystitis
IC involves overlapping pathologies — mucosal barrier dysfunction, mast cell activation, neuroinflammation and tissue hypoxia — that HBOT targets simultaneously at the bladder wall level.
Reduces bladder wall inflammation and mast cell activation
Promotes regeneration of the bladder mucosa
Improves pelvic tissue oxygenation
Reduces bladder pain and urinary urgency
Supports Hunner lesion healing
Modulates pelvic pain neuroinflammation
For Providers
Clinical evidence for HBOT in interstitial cystitis
The evidence base for HBOT in interstitial cystitis includes a randomized controlled trial and follow-up data, providing a stronger foundation than many IC treatments currently in use.
van Ophoven et al. — randomized sham-controlled trial (2004–2006): Arndt van Ophoven and colleagues conducted the landmark double-blind, sham-controlled RCT of HBOT in refractory interstitial cystitis, published in the European Urology. Patients with IC refractory to conventional therapies were randomized to 30 sessions of HBOT at 2.0 ATA or sham treatment. The HBOT group demonstrated statistically significant improvements on the O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and the IC Problem Index (ICPI) — the two primary validated outcome measures for IC — compared to the sham group. Approximately 50% of actively treated patients achieved clinically meaningful symptom reduction. [van Ophoven A et al. Eur Urol. 2004;46(1):65–72. PMID: 15183549]
van Ophoven et al. — 1-year follow-up: A subsequent publication confirmed that the symptom improvements achieved in the HBOT group were maintained at one-year follow-up, with no significant deterioration in ICSI or ICPI scores from post-treatment levels. This durability of response is clinically important in a condition characterized by waxing and waning symptoms. [van Ophoven A et al. Urology. 2005;66(5):956–960. PMID: 16286099]
Mast cell and neuroinflammation mechanism: IC pathophysiology involves abnormal bladder mast cell activation, with mast cell density correlating with symptom severity. HBOT’s well-documented suppression of mast cell degranulation and pro-inflammatory cytokine release (histamine, tryptase, TNF-α, IL-1β) provides a mechanistic basis for its benefit in IC that directly targets the primary inflammatory effector cell in the bladder wall.
Urothelial barrier repair: The glycosaminoglycan (GAG) layer deficiency that characterizes IC urothelium is supported by evidence that HBOT promotes epithelial repair through epidermal growth factor (EGF) upregulation, stem cell mobilization and VEGF-mediated angiogenesis in the submucosal tissue. These mechanisms directly address the mucosal barrier dysfunction that allows urinary components to penetrate and trigger the IC inflammatory cascade.
Weiss 1994 — pilot series: An earlier pilot case series by Weiss et al. documented significant improvements in IC symptoms in a small cohort of patients treated with HBOT, providing the initial clinical evidence that informed the subsequent randomized trial. [Weiss JM. J Urol. 1994;151(6):1612–1614. PMID: 8189592]
Our interstitial cystitis HBOT protocol at Bay Area Hyperbarics
HBOT for interstitial cystitis works best as an adjunct to — not a replacement for — conventional IC treatments. Patients with refractory IC who have not responded adequately to oral medications, bladder instillations or other standard therapies are the most appropriate candidates. We give an honest assessment of likely benefit at your consultation.
Urology assessment and treatment coordination
Our medical team reviews your IC diagnosis, symptom profile, prior treatments (bladder instillations, oral medications, hydrodistension, Botox), cystoscopy findings (including the presence or absence of Hunner lesions) and current treatment response. We coordinate with your urologist or urogynecologist to integrate HBOT into your ongoing IC management plan.
HBOT sessions to reduce inflammation and support bladder mucosal repair
You breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute for approximately 90 minutes per session. Interstitial cystitis protocols in published trials have used 30 to 60 sessions as initial treatment courses. Sessions are scheduled once daily, five days per week, and are continued concurrently with your ongoing IC medical management.
Symptom monitoring and maintenance planning
We track IC symptom scores, pain ratings, voiding frequency and quality of life using validated IC outcome measures throughout treatment. Given the chronic nature of IC, maintenance HBOT courses are often beneficial to sustain improvements. We develop a personalized long-term plan based on your treatment response and symptom trajectory.
Frequently Asked Questions
Answers to the questions interstitial cystitis patients most often ask about hyperbaric oxygen therapy.
Standard IC treatments — oral medications like pentosan polysulfate or amitriptyline, bladder instillations with DMSO or heparin, hydrodistension and Botox — primarily manage symptoms or target the urothelial surface. HBOT addresses the deeper bladder wall pathology: the chronic inflammation, mast cell activation and tissue hypoxia within the bladder wall itself. By suppressing these underlying inflammatory mechanisms and supporting mucosal repair from the tissue level, HBOT can produce improvements that bladder surface-directed treatments cannot achieve.
Living with interstitial cystitis? Ask us about HBOT
Bay Area Hyperbarics offers HBOT for interstitial cystitis patients who have not achieved adequate relief from conventional therapy. Our team will review your treatment history and discuss whether HBOT is likely to help in your specific case. Call us to schedule a consultation.
